started · updated
Orakl Oncology raises $34 million for AI cancer drug prediction
Paris-based TechBio startup Orakl Oncology has secured $34 million in a Series A funding round led by Norrsken VC and Singular. This investment brings the company’s total funding to $50 million.
Orakl Oncology, a spin-out from the Gustave Roussy oncology center, utilizes a platform that combines artificial intelligence with biological models to predict how cancer drugs will perform in patients. By using tumor organoids grown from real patient samples alongside medical and molecular data, the company creates virtual patient cohorts to test drug efficacy. This approach aims to address the high failure rate of oncology candidates during Phase 2 clinical trials.
Originally focused on colorectal and pancreatic cancers, the company plans to expand its research to include lung and gastric cancers. The new capital will also support the expansion of its AI research team and the establishment of new teams in the United States and the United Kingdom.
Entities
Fanny Jaulin · Gustave Roussy · Norrsken VC · Orakl Oncology · Singular